PMID- 30626832
OWN - NLM
STAT- MEDLINE
DCOM- 20190708
LR  - 20200225
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 58
IP  - 9
DP  - 2019 May 1
TI  - Clinical and Genetic Aspects of Behcet's Disease in Japan.
PG  - 1199-1207
LID - 10.2169/internalmedicine.2035-18 [doi]
AB  - Patients with Behcet's disease (BD) suffer from episodic ocular and mucocutaneous 
      attacks, resulting in a reduced quality of life. The phenotype of Japanese BD has 
      been changing over the past 20 years, and the rate of human leukocyte antigen 
      (HLA)-B*51-positive complete type is decreasing while that of intestinal type is 
      increasing. This phenotypical evolution may be related to changes in 
      as-yet-unknown environmental factors, as the immigration influx in Japan is low. 
      Mechanisms discovered by genome-wide association studies include ERAP1-mediated 
      HLA class I antigen bounding pathway, autoinflammation, Th17 cells, natural 
      killer cells, and polarized macrophages, a similar genetic architecture to 
      Crohn's disease, ankylosing spondylitis, and psoriasis. As for treatments, 
      management guidelines have been implemented, and the development of tumor 
      necrosis factor (TNF) inhibitors is markedly improving the outcome of BD, but 
      evidence supporting treatment for special-type BD is limited. The classification 
      of BD into distinct clusters based on clinical manifestations and genetic factors 
      is crucial to the development of optimized medicine.
FAU - Kirino, Yohei
AU  - Kirino Y
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University, Graduate 
      School of Medicine, Japan.
FAU - Nakajima, Hideaki
AU  - Nakajima H
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University, Graduate 
      School of Medicine, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190110
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.11.- (Aminopeptidases)
RN  - EC 3.4.11.- (ERAP1 protein, human)
SB  - IM
MH  - Aminopeptidases/metabolism
MH  - Behcet Syndrome/diagnosis/drug therapy/epidemiology/*genetics
MH  - Genetic Predisposition to Disease
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Japan/epidemiology
MH  - Killer Cells, Natural/immunology
MH  - Minor Histocompatibility Antigens/metabolism
MH  - Phenotype
MH  - Quality of Life
MH  - Risk Factors
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
PMC - PMC6543215
OTO - NOTNLM
OT  - Behcet's disease
OT  - ERAP1
OT  - GWAS
OT  - HLA
OT  - environmental factors
OT  - genetics
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2019/01/11 06:00
MHDA- 2019/07/10 06:00
PMCR- 2019/05/01
CRDT- 2019/01/11 06:00
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2019/01/11 06:00 [entrez]
PHST- 2019/05/01 00:00 [pmc-release]
AID - 10.2169/internalmedicine.2035-18 [doi]
PST - ppublish
SO  - Intern Med. 2019 May 1;58(9):1199-1207. doi: 10.2169/internalmedicine.2035-18. 
      Epub 2019 Jan 10.